Comparison of effects of amphotericin B deoxycholate infused over 4 or 24 hours: randomised controlled trial

被引:152
作者
Eriksson, U
Seifert, B
Schaffner, A
机构
[1] Univ Zurich, Univ Hosp, CH-8091 Zurich, Switzerland
[2] Univ Zurich, Dept Biostat, CH-8091 Zurich, Switzerland
来源
BMJ-BRITISH MEDICAL JOURNAL | 2001年 / 322卷 / 7286期
关键词
D O I
10.1136/bmj.322.7286.579
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective To test the hypothesis that amphotericin B deoxycholate is less toxic when given by continuous infusion than by conventional rapid infusion. Design Randomised, controlled, non-blinded, single centre study. Setting University hospital providing tertiary clinical care. Patients 80 mostly neutropenic patients with refractory fever and suspected or proved invasive fungal infections. Intervention Patients were randomised to receive 0.97 mg/kg amphotericin B by continuous infusion over 24 hours or 0.95 mg/kg by rapid infusion over four hours. Main outcome measures Patients were evaluated for side effects related to infusion, nephrotoxicity, and mortality up to three months after treatment Analysis was on an intention to treat basis. Results Patients in the continuous infusion group had fewer side effects and significantly reduced nephrotoxicity compared with those in the rapid infusion group, Overall mortality was higher during treatment and after three months' follow up in the rapid infusion than in the continuous infusion group. Conclusion Continuous infusions of amphotericin B reduce nephrotoxicity and side effects related to infusion without increasing mortality.
引用
收藏
页码:579 / 582
页数:4
相关论文
共 21 条
[11]   PRETREATMENT REGIMENS FOR ADVERSE EVENTS RELATED TO INFUSION OF AMPHOTERICIN-B [J].
GOODWIN, SD ;
CLEARY, JD ;
WALAWANDER, CA ;
TAYLOR, JW ;
GRASELA, TH .
CLINICAL INFECTIOUS DISEASES, 1995, 20 (04) :755-761
[12]   ESTIMATION OF A COMMON EFFECT PARAMETER FROM SPARSE FOLLOW-UP DATA [J].
GREENLAND, S ;
ROBINS, JM .
BIOMETRICS, 1985, 41 (01) :55-68
[13]   PREDICTION OF CREATININE CLEARANCE FROM SERUM CREATININE CONCENTRATION BASED ON LEAN BODY-MASS [J].
HALLYNCK, T ;
SOEP, HH ;
THOMIS, J ;
BOELAERT, J ;
DANEELS, R ;
FILLASTRE, JP ;
DEROSA, F ;
RUBINSTEIN, E ;
HATALA, M ;
SPOUSTA, J ;
DETTLI, L .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1981, 30 (03) :414-421
[14]   SHOULD CLEARANCE BE NORMALIZED TO BODY-SURFACE OR TO LEAN BODY-MASS [J].
HALLYNCK, TH ;
SOEP, HH ;
THOMIS, JA ;
BOELAERT, J ;
DANEELS, R ;
DETTLI, L .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1981, 11 (05) :523-526
[15]   Lipid formulations of amphotericin B: Recent progress and future directions [J].
Hiemenz, JW ;
Walsh, TJ .
CLINICAL INFECTIOUS DISEASES, 1996, 22 :S133-S144
[16]   LIPOSOMAL AMPHOTERICIN-B IN THE TREATMENT OF FUNGAL-INFECTIONS IN NEUTROPENIC PATIENTS - A SINGLE-CENTER EXPERIENCE OF 133 EPISODES IN 116 PATIENTS [J].
MILLS, W ;
CHOPRA, R ;
LINCH, DC ;
GOLDSTONE, AH .
BRITISH JOURNAL OF HAEMATOLOGY, 1994, 86 (04) :754-760
[17]   RANDOMIZED, DOUBLE-BLIND TRIAL OF 1-HOUR VERSUS 4-HOUR AMPHOTERICIN-B INFUSION DURATIONS [J].
OLDFIELD, EC ;
GARST, PD ;
HOSTETTLER, C ;
WHITE, M ;
SAMUELSON, D .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1990, 34 (07) :1402-1406
[18]   A randomized comparison of liposomal versus conventional amphotericin B for the treatment of pyrexia of unknown origin in neutropenic patients [J].
Prentice, HG ;
Hann, IM ;
Herbrecht, R ;
Aoun, M ;
Kvaloy, S ;
Catovsky, D ;
Pinkerton, CR ;
Schey, SA ;
Jacobs, F ;
Oakhill, A ;
Stevens, RF ;
Darbyshire, PJ ;
Gibson, BES .
BRITISH JOURNAL OF HAEMATOLOGY, 1997, 98 (03) :711-718
[19]   Amphotericin B activation of human genes encoding for cytokines [J].
Rogers, PD ;
Jenkins, JK ;
Chapman, SW ;
Ndebele, K ;
Chapman, BA ;
Cleary, JD .
JOURNAL OF INFECTIOUS DISEASES, 1998, 178 (06) :1726-1733
[20]  
Schöffski P, 1998, BRIT MED J, V317, P379, DOI 10.1136/bmj.317.7155.379